Clinical Trial: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional




Official Title: Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma

Brief Summary: This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.